Citations

Clear

9383 citation(s) found for "Thomas, PS".

Development and characterization of a conditionally immortalized human fetal osteoblastic cell line
Harris, Steven A. , Enger, Robert J., Riggs, Lawrence B., Spelsberg, Thomas C.

Mayo Clinic

Journal of Bone and Mineral Research | February 3, 2010 | Volume: 10 | Issue: 2 | Pages: 178-186

10.1002/jbmr.5650100203 | PMID 7754797 Get It

Abstract We report the establishment of a human fetal osteoblast cell line derived from biopsies obtained from a spontaneous miscarriage. Primary cultures isolated from fetal tissue were transfected with a gene coding for a temperature-sensitive mutant (tsA58) of SV40 large T antigen along with a gene coding for neomycin (G418) resistance. Individual neomycin resistant colonies were screened for alkaline phosphatase (AP)-specific staining. The clone with the highest AP level, hFOB 1.19, was examined further for other osteoblast phenotypic markers. Incubation of hFOB cells at the permissive temperature (33.5°C) resulted in rapid cell division, whereas little or no cell division occurred at the restrictive temperature (39.5°C). Both AP activity and osteocalcin (OC) secretion increased in a dose-dependent manner following dihydroxyvitamin D3 (1,25-D3) treatment when cultured at either temperature. However, AP and 1,25-D3-induced OC levels were elevated in confluent hFOB cells cultured at 39.5°C compared with 33.5°C. Treatment of hFOB cells with 1–34 parathyroid hormone (PTH) resulted in an increase in cAMP levels. Upon reaching confluence, hFOB cultures went through programmed differentiation and formed mineralized nodules as observed by von Kossa staining. Further, immunostaining of postconfluent, differentiated hFOB cells showed that high levels of osteopontin, osteonectin, bone sialoprotein, and type I collagen were expressed. Therefore, the clonal cell line hFOB 1.19 provides a homogeneous, rapidly proliferating model system to study certain stages of human osteoblast differentiation.
TIEG1-NULL OSTEOCYTES DISPLAY DEFECTS IN THEIR MORPHOLOGY, DENSITY AND SURROUNDING BONE MATRIX
Hawse, John R. , Subramaniam, Malayannan , Spelsberg, Thomas C., Bensamoun, Sabine F. , Haddad, Oualid , Bensamoun, Sabine F

Mayo Clinic

Journal of Musculoskeletal Research | January 28, 2010 | Volume: 12 | Issue: 03 | Pages: 127-136

10.1142/s0218957709002304 | PMID 22121306 Get It

Through the development of TGFβ-inducible early gene-1 (TIEG1) knockout (KO) mice, we have demonstrated that TIEG1 plays an important role in osteoblast-mediated bone mineralization, and in bone resistance to mechanical strain. To further investigate the influence of TIEG1 in skeletal maintenance, osteocytes were analyzed by transmission electron microscopy using TIEG1 KO and wild-type mouse femurs at one, three and eight months of age. The results revealed an age-dependent change in osteocyte surface and density, suggesting a role for TIEG1 in osteocyte development. Moreover, there was a decrease in the amount of hypomineralized bone matrix surrounding the osteocytes in TIEG1 KO mice relative to wild-type controls. While little is known about the function or importance of this hypomineralized bone matrix immediately adjacent to osteocytes, this study reveals significant differences in this bone microenvironment and suggests that osteocyte function may be compromised in the absence of TIEG1 expression.
Dose and Image Quality Evaluation of a Dedicated Cone-Beam CT System for High-Contrast Neurologic Applications
Yu, Lifeng , Vrieze, Thomas J., Bruesewitz, Michael R. , Kofler, James M., DeLone, David R. , Pallanch, John F., Lindell, E. Paul , Yu, Lifeng , McCollough, Cynthia H.

Mayo Clinic

American Journal of Roentgenology | January 21, 2010 | Volume: 194 | Issue: 2 | Pages: W193-W201

10.2214/ajr.09.2951 | PMID 20093573 Get It

Influence of Locomotor Muscle Metaboreceptor Stimulation on the Ventilatory Response to Exercise in Heart Failure
Olson, Thomas P. , Joyner, Michael J. , Johnson, Bruce D. , Joyner, Michael J

Mayo Clinic

Circulation: Heart Failure | January 9, 2010 | Volume: 3 | Issue: 2 | Pages: 212-219

10.1161/circheartfailure.109.879684 | PMID 20061520 Get It

Background— Whether locomotor muscle afferent neural activity contributes to exercise hyperpnea and symptoms of dyspnea in heart failure (HF) is controversial. We examined the influence of metaboreceptor stimulation on ventilation with and without maintaining end-exercise end-tidal CO 2 levels. Methods and Results— Eleven patients with HF aged 51±5 years (ejection fraction, 32±3%; New York Heart Association class, 1.6±0.2) and 11 age- and gender-matched healthy control participants aged 43±3 years were studied. Participants underwent 3 steady-state cycling sessions at 60% of peak oxygen consumption for 4 minutes. The first exercise session was a baseline control trial. Bilateral thigh tourniquets were inflated to suprasystolic pressure at end exercise for 2 minutes during 2 of the trials (regional circulatory occlusion) with the addition of inspired CO 2 to maintain end-exercise partial pressure of end-tidal CO 2 during 1 trial (regional circulatory occlusion+CO 2 ). Minute ventilation was measured continuously throughout each trial. At 2 minutes postexercise during the baseline control trial in patients with HF, minute ventilation was 54% of end exercise, whereas the control group averaged 41% ( P =0.11). During regional circulatory occlusion in patients with HF, minute ventilation was 60% of end exercise; however, the control group averaged 35% ( P <0.001). During regional circulatory occlusion+CO 2 , the minute ventilation of patients with HF averaged 67% of end exercise, whereas the control group averaged 44% ( P <0.001). Conclusion— These data suggest that increased afferent neural activity from the large locomotor muscles associated with metabolites generated during exercise contribute to the augmented ventilatory response to exercise in patients with HF.
Clinical Predictors of a Diagnosis of Idiopathic Pulmonary Fibrosis
Fell, Charlene D. , Liu, Lyrica X., Murray, Susan , Han, MeiLan K., Kazerooni, Ella A. , Gross, Barry H., Colby, Thomas V. , Toews, Galen B., Flaherty, Kevin R. , Martínez, Fernando J. , Han, MeiLan King , Myers, Jeffrey L. , Travis, William D.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | January 7, 2010 | Volume: 181 | Issue: 8 | Pages: 832-837

10.1164/rccm.200906-0959oc | PMID 20056903 Get It

Abstract Rationale Idiopathic pulmonary fibrosis (IPF) and other idiopathic interstitial pneumonias (IIPs) have similar clinical and radiographic features, but their histopathology, response to therapy, and natural history differ. A surgical lung biopsy is often required to distinguish between these entities. Objectives We sought to determine if clinical variables could predict a histopathologic diagnosis of IPF in patients without honeycomb change on high-resolution computed tomography (HRCT). Methods Data from 97 patients with biopsy-proven IPF and 38 patients with other IIPs were examined. Logistic regression models were built to identify the clinical variables that predict histopathologic diagnosis of IPF. Measurements and Main Results Increasing age and average total HRCT interstitial score on HRCT scan of the chest may predict a biopsy confirmation of IPF. Sex, pulmonary function, presence of desaturation, or distance walked during a 6-minute walk test did not help discriminate pulmonary fibrosis from other IIPs. Conclusions Clinical data may be used to predict a diagnosis of IPF over other IIPs. Validation of these data with a prospective study is needed.
Design of the Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST)
Sheffet, Amiram, Roubin, Gary S., Howard, George , Howard, Virginia J. , Moore, Wesley S. , Hobson, R W, Brott, Thomas G. , Meschia, James F. , Howard, Virginia J , Howard, George

Mayo Clinic

International Journal of Stroke | January 7, 2010 | Volume: 5 | Issue: 1 | Pages: 40-46

10.1111/j.1747-4949.2009.00405.x | PMID 20088993 Get It

Rationale Carotid endarterectomy (CEA) and medical therapy were shown superior to medical therapy alone for symptomatic (ge;50%) and asymptomatic (≥60%) stenosis. Carotid angioplasty stenting (CAS) offers a less invasive alternative. Establishing safety, efficacy, and durability of CAS requires rigorous comparison with CEA in symptomatic and asymptomatic patients. Aims The objective is to compare the efficacy of CAS versus CEA in patients with symptomatic (≥50%) or asymptomatic (≥60%) extracranial carotid stenosis. Design The Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST) is a prospective, randomized, parallel, two-arm, multi-center trial with blinded endpoint adjudication. Primary endpoints are analyzed using standard time-to-event statistical modeling with adjustment for major baseline covariates. Primary analysis is on an intent-to-treat basis. Study Outcomes The primary outcome is the occurrence of any stroke, myocardial infarction, or death during a 30-day peri-procedural period, and ipsilateral stroke during follow-up of up to four years. Secondary outcomes include restenosis and health-related quality of life.
Alternating Systemic and Hepatic Artery Infusion Therapy for Resected Liver Metastases From Colorectal Cancer: A North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) Phase II Intergroup Trial, N9945/CI-6
Mahoney, Michelle R., Nagorney, David M. , Wagman, Lawrence D., Smyrk, Thomas C. , Weiland, Timothy L., Lai, Lily , Schwarz, Roderich E. , Molina, R, Dentchev, Todor, Bolton, John S. , Alberts, Steven R. , Roh, Mark S. , O’Connell, Michael J.

Mayo Clinic

Journal of Clinical Oncology | January 5, 2010 | Volume: 28 | Issue: 5 | Pages: 853-858

10.1200/jco.2009.24.6728 | PMID 20048179 Get It

Purpose Prior trials have shown that surgery followed by hepatic artery infusion (HAI) of floxuridine (FUDR) alternating with systemic fluorouracil improves survival rates. Oxaliplatin combined with capecitabine has demonstrated activity in advanced colorectal cancer. Based on this observation a trial was conducted to assess the potential benefit of systemic oxaliplatin and capecitabine alternating with HAI of FUDR. The primary end point was 2-year survival. Patients and Methods Patients with liver-only metastases from colorectal cancer amenable to resection or cryoablation were eligible. HAI and systemic therapy was initiated after metastasectomy. Alternating courses of HAI consisted of 0.2 mg/m2/d FUDR and dexamethasone, day 1 through 14 weeks 1 and 2. Systemic therapy included oxaliplatin 130 mg/m2 day 1 with capecitabine at 1,000 mg/m2 twice daily, days 1 through 14, weeks 4 and 5. Two additional 3-week courses of systemic therapy were given. Capecitabine was reduced to 850 mg/m2 twice daily after interim review of toxicity. Results Fifty-five of 76 eligible patients were able to initiate protocol-directed therapy and completed median of six cycles (range, one to six). Three postoperative or treatment-related deaths were reported. Overall, 88% of evaluable patients were alive at 2 years. With a median follow-up of 4.8 years, a total of 30 patients have had disease recurrence, 11 involving the liver. Median disease-free survival was 32.7 months. Conclusion Alternating HAI of FUDR and systemic capecitabine and oxaliplatin met the prespecified end point of higher than 85% survival at 2 years and was clinically tolerable. However, the merits of this approach need to be established with a phase III trial.
Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia
Litzow, Mark R. , Tarima, Sergey , Pérez, Waleska S., Bolwell, Brian J., Cairo, Mitchell S. , Camitta, Bruce M., Luger, Selina M. , Marks, David I. , Pasquini, Marcelo C. , Phillips, Gordon L., Rizzo, J. Douglas , Sierra, Jorge , Tallman, Martin S. , Weisdorf, Daniel J. , Cutler, Corey S. , Lima, Marcos de , DiPersio, John F. , Gale, Robert Peter , Keating, Armand , Lazarus, Hillard M. , Maziarz, Richard Thomas , McCarthy, Philip L. , Weisdorf, Dan

Mayo Clinic

Blood | December 24, 2009 | Volume: 115 | Issue: 9 | Pages: 1850-1857

10.1182/blood-2009-10-249128 | PMID 20032503 Get It

Abstract Therapy-related myelodysplastic syndromes (t-MDSs) and acute myeloid leukemia (t-AML) have a poor prognosis with conventional therapy. Encouraging results are reported after allogeneic transplantation. We analyzed outcomes in 868 persons with t-AML (n = 545) or t-MDS (n = 323) receiving allogeneic transplants from 1990 to 2004. A myeloablative regimen was used for conditioning in 77%. Treatment-related mortality (TRM) and relapse were 41% (95% confidence interval [CI], 38-44) and 27% (24-30) at 1 year and 48% (44-51) and 31% (28-34) at 5 years, respectively. Disease-free (DFS) and overall survival (OS) were 32% (95% CI, 29-36) and 37% (34-41) at 1 year and 21% (18-24) and 22% (19-26) at 5 years, respectively. In multivariate analysis, 4 risk factors had adverse impacts on DFS and OS: (1) age older than 35 years; (2) poor-risk cytogenetics; (3) t-AML not in remission or advanced t-MDS; and (4) donor other than an HLA-identical sibling or a partially or well-matched unrelated donor. Five-year survival for subjects with none, 1, 2, 3, or 4 of these risk factors was 50% (95% CI, 38-61), 26% (20-31), 21% (16-26), 10% (5-15), and 4% (0-16), respectively (P < .001). These data permit a more precise prediction of outcome and identify subjects most likely to benefit from allogeneic transplantation.
Mutability in the Matrix Gene of Novel Influenza A H1N1 Virus Detected Using a FRET Probe-Based Real-Time Reverse Transcriptase PCR Assay
Dhiman, Neelam , Espy, Mark J., Irish, Cole L., Wright, Patty , Smith, Thomas F., Pritt, Bobbi S. , Pritt, Bobbi S

Mayo Clinic

Journal of Clinical Microbiology | December 17, 2009 | Volume: 48 | Issue: 2 | Pages: 677-679

10.1128/jcm.02225-09 | PMID 20018814 Get It